The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): Design and baseline characteristics

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Microalbuminuria is an early marker of diabetic nephropathy and its prevention is considered key for the primary prevention of diabetic nephropathy. Angiotensin-converting enzyme (ACE) inhibitors and nondihydropyridine calcium channel blockers (CCBs) have specific renoprotective properties in diabetes, and preliminary evidence is available that they are more effective in combination than either of the two agents alone in limiting albuminuria either in micro- or macroalbuminuric type 2 diabetic patients. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) is a prospective, randomized, double-blind parallel-group study primarily aimed at evaluating the possibility of preventing the progression to microalbuminuria (urinary albumin excretion [UAE] rate 20-200 μg/min, i.e., incipient nephropathy) in 1209 hypertensive, type 2 diabetic patients with a normal UAE rate (

Original languageEnglish
Pages (from-to)442-461
Number of pages20
JournalControlled Clinical Trials
Volume24
Issue number4
DOIs
Publication statusPublished - Aug 2003

Fingerprint

Diabetic Nephropathies
Diabetes Complications
Albumins
Albuminuria
Calcium Channel Blockers
Primary Prevention
Angiotensin-Converting Enzyme Inhibitors

Keywords

  • ACE inhibitors
  • Calcium channel blockers
  • Diabetic nephropathy
  • Hypertension
  • Microalbuminuria
  • NIDD
  • Normoalbuminuria
  • Primary prevention

ASJC Scopus subject areas

  • Pharmacology

Cite this

The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) : Design and baseline characteristics. / Perna, Annalisa.

In: Controlled Clinical Trials, Vol. 24, No. 4, 08.2003, p. 442-461.

Research output: Contribution to journalArticle

@article{b65b03108b274dee80915ee04d7ba05f,
title = "The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): Design and baseline characteristics",
abstract = "Microalbuminuria is an early marker of diabetic nephropathy and its prevention is considered key for the primary prevention of diabetic nephropathy. Angiotensin-converting enzyme (ACE) inhibitors and nondihydropyridine calcium channel blockers (CCBs) have specific renoprotective properties in diabetes, and preliminary evidence is available that they are more effective in combination than either of the two agents alone in limiting albuminuria either in micro- or macroalbuminuric type 2 diabetic patients. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) is a prospective, randomized, double-blind parallel-group study primarily aimed at evaluating the possibility of preventing the progression to microalbuminuria (urinary albumin excretion [UAE] rate 20-200 μg/min, i.e., incipient nephropathy) in 1209 hypertensive, type 2 diabetic patients with a normal UAE rate (",
keywords = "ACE inhibitors, Calcium channel blockers, Diabetic nephropathy, Hypertension, Microalbuminuria, NIDD, Normoalbuminuria, Primary prevention",
author = "Annalisa Perna",
year = "2003",
month = "8",
doi = "10.1016/S0197-2456(03)00028-X",
language = "English",
volume = "24",
pages = "442--461",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT)

T2 - Design and baseline characteristics

AU - Perna, Annalisa

PY - 2003/8

Y1 - 2003/8

N2 - Microalbuminuria is an early marker of diabetic nephropathy and its prevention is considered key for the primary prevention of diabetic nephropathy. Angiotensin-converting enzyme (ACE) inhibitors and nondihydropyridine calcium channel blockers (CCBs) have specific renoprotective properties in diabetes, and preliminary evidence is available that they are more effective in combination than either of the two agents alone in limiting albuminuria either in micro- or macroalbuminuric type 2 diabetic patients. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) is a prospective, randomized, double-blind parallel-group study primarily aimed at evaluating the possibility of preventing the progression to microalbuminuria (urinary albumin excretion [UAE] rate 20-200 μg/min, i.e., incipient nephropathy) in 1209 hypertensive, type 2 diabetic patients with a normal UAE rate (

AB - Microalbuminuria is an early marker of diabetic nephropathy and its prevention is considered key for the primary prevention of diabetic nephropathy. Angiotensin-converting enzyme (ACE) inhibitors and nondihydropyridine calcium channel blockers (CCBs) have specific renoprotective properties in diabetes, and preliminary evidence is available that they are more effective in combination than either of the two agents alone in limiting albuminuria either in micro- or macroalbuminuric type 2 diabetic patients. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) is a prospective, randomized, double-blind parallel-group study primarily aimed at evaluating the possibility of preventing the progression to microalbuminuria (urinary albumin excretion [UAE] rate 20-200 μg/min, i.e., incipient nephropathy) in 1209 hypertensive, type 2 diabetic patients with a normal UAE rate (

KW - ACE inhibitors

KW - Calcium channel blockers

KW - Diabetic nephropathy

KW - Hypertension

KW - Microalbuminuria

KW - NIDD

KW - Normoalbuminuria

KW - Primary prevention

UR - http://www.scopus.com/inward/record.url?scp=0037628383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037628383&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(03)00028-X

DO - 10.1016/S0197-2456(03)00028-X

M3 - Article

C2 - 12865039

AN - SCOPUS:0037628383

VL - 24

SP - 442

EP - 461

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 4

ER -